Trials / Completed
CompletedNCT02589457
Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet (Tenofovir Disoproxil Aspartate) With Viread® Tablet (Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety and pharmacokinetics of CKD-390(Tenofovir Disoproxil Aspartate) and Viread® tablet(Tenofovir Disoproxil Fumarate) in healthy male volunteers.
Detailed description
A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet (Tenofovir Disoproxil Aspartate) With Viread® Tablet (Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-390 | Tenofovir Disoproxil Aspartate 1T PO |
| DRUG | Viread® tablet | Tenofovir Disoproxil Fumarate 1T PO |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2015-10-28
- Last updated
- 2016-01-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02589457. Inclusion in this directory is not an endorsement.